Panachai Nimitpanya

Dr. Panachai Nimitpanya

King Chulalongkorn Memorial Hospital, Bangkok, Krung Thep Maha Nakhon, Thailand
+1

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
SSSiriporn Srirungruang
Siriporn Srirungruang
BMBuraya Mahajindawong
Buraya Mahajindawong
PNPanachai Nimitpanya
Panachai Nimitpanya
UBUthaitip Bunkasem
Uthaitip Bunkasem
PAPattama Ayuyoe
Pattama Ayuyoe
VSVivornpun Sanprasert
Vivornpun Sanprasert
Stool samples typically contain PCR inhibitors; however, helminths are difficult to lyse and can cause false-negative PCR results. We assessed the effective methods for extracting DNA from different kinds of intestinal parasites. We compared the most common DNA extraction methods from stool samples, including the phenol-chloroform technique with or without a bead-beating step (P and PB), a QIAamp Fast DNA Stool Mini Kit (Q), and a QIAamp PowerFecal Pro DNA Kit (QB). Genomic DNA was extracted from 85 stool samples collected from patients infected with Blastocystis sp., Ascaris lumbricoides, Trichuris trichiura, hookworm, and Strongyloides stercoralis. DNA quantity and DNA quality were evaluated via spectrophotometry, and DNA integrity was assessed by PCR. We found that P and PB provided higher DNA yields (~4 times) than when using Q and QB. However, P showed the lowest detection rate of PCR (8.2%), wherein only S. stercoralis (7 out of 20 samples) was detected. QB showed the highest detection rate of PCR (61.2%). After plasmid spikes, only 5 samples by QB were negative while 60 samples by P were still negative. Remarkably, QB could extract DNA from all the groups of parasites that we tested. These results indicate that QB is the most effective DNA extraction method for the diagnosis and monitoring of intestinal parasites via PCR.

23 September 2024 in Transgender Health
Verified
Journal Article
Closed access
PPPunika Panichaya
Punika Panichaya
KPKrasean Panyakhamlerd
Krasean Panyakhamlerd
ASAmmarin Suwan
Ammarin Suwan
CAChai Ariyasriwatana
Chai Ariyasriwatana
SVSuthida Visedthorn
Suthida Visedthorn
PNPanachai Nimitpanya
Panachai Nimitpanya
Purpose: Sex hormone levels affect the composition of vaginal flora. Changes in the vaginal microbiome affect overall health. Among transgender men (TM) who receive gender-affirming treatment, there can be changes in the vaginal microbiome, causing adverse effects that are usually neglected by both transgender individuals and health care professionals. This study aimed to elucidate the effect of testosterone on the vaginal microbiome. Methods: This prospective study was conducted at King Chulalongkorn Memorial Hospital, Thailand, from January 2021 to June 2023. All patients who were TM and had not received testosterone were included in the study. High-throughput sequencing was used to evaluate bacterial community profiles. Testosterone enanthate 150 mg was administered via intramuscular injection every three weeks. Vaginal health was reevaluated 12 weeks after treatment. The primary objective of this study was to compare the vaginal microbiomes before and after testosterone replacement therapy. Results: Twenty-six participants were included in this study. Compared with pre-testosterone treatment, testosterone-treated TM had a lower likelihood of having Lactobacillus spp. as the dominant bacterial species, a considerably higher relative bacterial abundance of various species, and higher alpha diversity ( p < 0.01). Clinically, after administering testosterone for 12 weeks, the participants reported more symptoms ( p = 0.04), higher vaginal atrophy scores ( p < 0.01), a lower normal flora index ( p < 0.01), higher vaginal pH ( p < 0.01), and worse scores for vaginal maturation values ( p < 0.01). Conclusion: The use of testosterone in TM may alter the vaginal microbiota by decreasing Lactobacillus colonization and increasing alpha diversity. The Clinical Trials Registration number is TCTR20210202007 (Thai Clinical Trials Registry).

4 March 2025 in International Journal of Transgender Health
Verified
Journal Article
Closed access
VVVichadet Vichuladda
Vichadet Vichuladda
ASAmmarin Suwan
Ammarin Suwan
KPKrasean Panyakhamlerd
Krasean Panyakhamlerd
SCSuchanant Chavaengkiat
Suchanant Chavaengkiat
PNPanachai Nimitpanya
Panachai Nimitpanya
Testosterone therapy is a standard intervention for improving both physical and mental health in transmasculine individuals. The aim of this study is to identify the effects of testosterone on the quality of life and sexual function among hormone-naïve transmasculine individuals in Thailand. This prospective study was conducted at King Chulalongkorn Memorial Hospital, Bangkok, Thailand from September 2022 to February 2024. Transmasculine individuals who met the inclusion criteria were invited to complete two questionnaires: the World Health Organization Quality of Life BREF THAI (WHO-QOL-BREF-THAI) and the female sexual function index (FSFI). Testosterone enanthate, 250 milligrams, was administered intramuscularly every 4 wk. Both questionnaires were reevaluated at 12 wk after initiation of testosterone therapy. A total of 55 hormone naïve transmasculine individuals were recruited. After a 12-wk period of testosterone therapy, the WHO-QOL-BREF-THAI mean total score was significantly higher compared to baseline (94.3 versus 101.4 out of 130, p < 0.001). Moreover, the mean scores in all particular WHO-QOL-BREF-THAI domains were also significantly different. Percentages of participants who reported good quality of life according to WHO-QOL-BREF-THAI score at 12 wk were significantly higher compared to baseline (69.1% versus 43.6%, p = 0.004). Among 34 participants who were sexually active throughout the study, there were significantly better total FSFI, desire domain, and orgasm domain scores at 12 wk of treatment compared to baseline (28.0 vs 24.2, 4.5 vs 3.4, and 4.6 vs 3.7, p = 0.022, <0.001 and 0.017, respectively). Hormone naïve-transmasculine individuals demonstrated significantly higher overall quality of life as early as 12 wk after testosterone therapy. Among transmasculine individuals who were sexually active, total FSFI, sexual desire, and orgasm scores were also significantly better compared to baseline. The longer-term effects of testosterone therapy on quality of life and sexual function among TM need to be elucidated in further studies.

20 December 2024 in Transgender Health
Verified
Journal Article
Closed access
PNPanachai Nimitpanya
Panachai Nimitpanya
KPKrasean Panyakhamlerd
Krasean Panyakhamlerd
ASAmmarin Suwan
Ammarin Suwan
VVVichadet Vichuladda
Vichadet Vichuladda
SVSira Vachatimanont
Sira Vachatimanont
PPPunika Panichaya
Punika Panichaya
Purpose: This study aimed to investigate the early impacts of masculinizing hormone therapy on body composition among testosterone-naive Thai transmasculine (TM) individuals, focusing on changes in fat and lean mass within the initial 3–6 months of treatment. Methods: In total, 32 participants were enrolled in this prospective study, receiving a 6-month course of 250-mg intramuscular testosterone enanthate. The assessment included whole-body dual X-ray absorptiometry, alongside anthropometric and laboratory evaluations. Results: After 6 months of testosterone administration, a significant reduction in total fat mass (FM) was observed (−4.5%; 95% confidence interval [CI] −8.5 to −0.5). Concurrently, there was an increase in total fat-free mass (FFM) (7.0%; 95% CI 3.3 to 10.8). Stratifying participants based on the World Health Organization Asian obesity criteria (body mass index <23 kg/m 2 for normal and ≥23 kg/m 2 for overweight-obesity), an elevation in FFM was observed in both categories, with a significant FM reduction only among individuals with obesity. Additional findings included hemoconcentration, reduced high-density lipoprotein cholesterol (HDL-C), and a decline in sex hormone-binding globulin (SHBG). Conclusions: Within a brief timeframe of testosterone therapy, a substantial decrease in FM and an increase in FFM were noted. Notably, this reduction in FM was more prominent in participants with obesity. Various alterations in laboratory parameters, such as hemoconcentration, reduced HDL-C, and diminished SHBG, were attributed to changes in hepatic metabolism and pituitary suppression induced by exogenous testosterone. These findings contribute valuable insights into the nuanced effects of hormone therapy on body composition among the TM population. Clinical Trial Registration Number—TCTR20241004001.

31 March 2026 in Pediatric and Developmental Pathology
Verified
Journal Article
Closed access
JWJutamas Wongphoom
Jutamas Wongphoom
PNPanachai Nimitpanya
Panachai Nimitpanya
NANawaluk Atiroj
Nawaluk Atiroj
MTMana Taweevisit
Mana Taweevisit
PTPaul Scott Thorner
Paul Scott Thorner
Introduction: CD15 expression has been used as a marker of endothelial immaturity in the placenta and is linked to the setting of antenatal hypoxia. If so, expression should be increased in fetal anemia, especially when severe enough to cause hydrops fetalis. This has not been previously reported and the current study tested this hypothesis. Materials and Methods: The study group consisted of 10 cases of anemic hydrops in second to early third trimester of gestation and 10 controls matched for gestational age. The majority (70%) of hydrops cases were due to hemoglobin (Hb) Bart. Placentas underwent CD15 immunohistochemical staining and results were quantitatively assessed by counting 100 vessels in each case. Results: For the anemic group, the mean number of CD15+ vessels was 52.0% in the proximal vasculature and 91.3% in the distal vasculature. Values for controls were 32.9% and 42.2%, respectively. The CD15 expression in the distal vasculature was significantly higher in the anemic hydrops group ( P < .001), but not significantly higher for the proximal vasculature ( P = .14). In the control group, the number of CD15+ vessels decreased with increasing gestational age for both proximal and distal vasculatures. In contrast, in the anemic hydrops group, the number of CD15+vessels did not significantly change with gestational age, for both the proximal and distal vasculatures. Conclusion: Placentas belonging to anemic hydrops cases demonstrate significantly increased expression of CD15 in the distal vasculature. CD15 expression in HF may be driven by hypoxia, reflecting an attempt by the placenta to compensate for this.

6 January 2022 in Pediatric and Developmental Pathology
Verified
Journal Article
Closed access
PDF file
MTMana Taweevisit
Mana Taweevisit
PNPanachai Nimitpanya
Panachai Nimitpanya
PTPaul S. Thorner
Paul S. Thorner
Maternal floor infarction (MFI) and massive perivillous fibrin deposition (MPFD) are overlapping placental disorders of unknown etiology, associated with adverse obstetric outcome, and a significant risk of recurrence. We describe a 31-year-old mother with asymptomatic thrombocytopenia throughout pregnancy and a positive lupus anticoagulant. She delivered a normal female neonate at term, whose weight was small for gestational age, with a placenta weighing less than the 10th percentile. Placental examination showed MPFD together with excessive subchorionic fibrinoid deposition. The placenta showed diffuse C4d deposition and an immune-mediated reaction was postulated for the pathogenesis of the placental changes. We suggest that excessive subchorionic fibrinoid deposition may be part of the morphologic spectrum of MFI/MPFD.